Background: Hepatitis B virus (HBV) nucleic acid amplification testing (NAAT) is important for the diagnosis and management of HBV infection. We evaluated the analytical performance of the cobas HBV NAAT (Roche Diagnostics GmbH, Mannheim, Germany) on the cobas 4800 System in comparison with COBAS AmpliPrep/COBAS TaqMan HBV Test (CAP/CTM HBV). Methods: Precision was evaluated using three levels of cobas HBV/HCV/HIV-1 Control Kit, and linearity was evaluated across the anticipated measuring range (10.0-1.0 × 10 9 IU/mL) at seven levels using clinical samples. Detection capability, including limit of blank (LOB), limit of detection (LOD) and limit of quantitation (LOQ), was verified using the 4th WHO International Standard for HBV DNA for NAT (NIBSC code: 10/266). Correlation between the two systems was compared using 205 clinical samples (102 sera and 103 EDTA plasma). Results: Repeatability and total imprecision (coefficient of variation) ranged from 0.5% to 3.8% and from 0.5% to 3.5%, respectively. Linearity (coefficient of determination, R 2 ) was 0.999. LOB, LOD and LOQ were all acceptable within the observed proportion rate (85%). Correlation was very high between the two systems in both serum and plasma samples (correlation coefficient [r] = 0.995).
Introduction
Hepatitis B virus (HBV), a member of the hepadnavirus family, is an enveloped, partially double-stranded virus. HBV gains entry into the hepatocytes and interferes with the function of the liver by replicating in hepatocytes [1] . Hepatitis B is a potentially life-threatening viral infection and can cause both acute and chronic liver diseases; more than 257 million people worldwide are living with HBV infection, and it accounts for approximately 887,000 deaths annually [2, 3] . Therefore, hepatitis B is a serious public health problem requiring early diagnosis and timely treatment [4] .
Serology, viral culture, antigen detection and viral nucleic acid amplification testing (NAAT) can be applied for diagnosis and monitoring of HBV infection [5] . Serological markers can neither differentiate between past and present infections nor discriminate antigenic variations, genotypes and presence of silent carriers and absence of antibody in early phase of infection [4, 6] . Detection of HBV DNA using NAAT is important for early diagnosis and appropriate management of HBV infection, and many automated real-time PCR systems are available in clinical laboratories [7] [8] [9] . When a new real-time PCR system is introduced to clinical practice, its analytical performance should be evaluated, and many factors should be considered such as sample volume, measurable range, available sample type and detection capabilities [10, 11] .
The new cobas HBV assay (Roche Diagnostics GmbH, Mannheim, Germany) is suit on the cobas 4800 System (Roche Diagnostics GmbH). We evaluated the analytical performance of cobas HBV on the cobas 4800 System in comparison with COBAS AmpliPrep/COBAS TaqMan HBV Test version 2.0 (CAP/CTM HBV) using the COBAS CAP/ CTM system that has been widely used for a long time and can be considered the gold standard.
Materials and methods

Test systems
The cobas 4800 System consists of cobas ×480 instrument and cobas z480 analyzer. The cobas HBV is an in vitro NAAT for the quantitation of HBV DNA in human EDTA plasma or serum using the cobas 4800 System by a silica-based capture technique using magnetic glass particles [12] . The processing volume is 200 μL or 400 μL, and its measurable range is 10-1 × 10 9 IU/mL. The CAP/CTM system consists of the COBAS AmpliPrep instrument (CAP) and COBAS TaqMan analyzer (CTM) using the docking system. COBAS CAP/CTM HBV Test (version 2.0) is an in vitro NAAT for the quantitation of HBV DNA in human EDTA plasma or serum using the COBAS CAP/CTM system by a silica-based capture technique using magnetic glass particles [13] . The processing volume is 500 μL, and its measurable range is 20-1.7 × 10 8 IU/mL.
Study design and performance evaluation
This in vitro evaluation study was conducted in Konkuk University Medical Center, Seoul, Korea, in April 2017 after getting exemption from approval by the Institutional Review Board of Konkuk University Medical Center (KUH1200082) to use remnant clinical samples. For the analytical performance of cobas HBV, precision, linearity and detection capability, including limit of blank (LOB), limit of detection (LOD) and limit of quantitation (LOQ), were evaluated. Correlation was evaluated in comparison with CAP/CTM HBV. Precision of cobas HBV was determined using two levels of cobas HBV/HCV/HIV-1 Control Kit (2.0 and 6.0 log 10 IU/mL) and one level of 1:1 mixture (using low and high levels, 4.0 log 10 IU/mL) of cobas HBV/HCV/HIV-1 Control Kit, according to the CLSI document EP15-A3 [14] . We replicated the test five times in a single run, on each of 5 days.
Linearity of cobas HBV was evaluated across the anticipated measuring range (10.0-1.0 × 10 9 IU/mL) at seven levels using one clinical sample with viral load of 427,000,000 IU/mL, according to the process outlined by the CLSI document EP06-A [15] . The sample was diluted serially with human plasma that did not contain detectable HBV DNA, and then the dilutions were analyzed in triplicate.
Detection capability of cobas HBV was estimated according to the CLSI document EP17-A2 [16] . To verify LOB claim, two blank samples were measured with four replicates per sample on each of 3 days using one reagent lot. Manufacturer-claimed concentrations of LOD and LOQ were 4.4 and 10.0 IU/mL, respectively; to verify them, the WHO standard material was diluted as 4.75 and 9.55 IU/mL, respectively. LOD and LOQ were verified using each two samples at the LOD and LOQ claimed concentrations. The two samples were measured four replicates per sample on each of 3 days using one reagent lot. Therefore, the total number of measurements in this study was 24 each for LOB, LOD and LOQ. The 4th WHO International Standard for HBV DNA for NAT (NIBSC code: 10/266) is intended to be used for the calibration of secondary reference reagents used in HBV NAAT. This material has been assigned a unit of 955,000 IU/mL (~5.98 log 10 IU/ mL) when reconstituted in 0.5 mL of deionized, nuclease-free molecular-grade water. The uncertainty may be considered to be ±0.36% [17] .
The quantitative results of HBV detection between cobas HBV and CAP/CTM HBV were compared, according to the CLSI document EP09-A3 [18] . A total of 205 clinical samples (102 sera and 103 EDTA plasma) were used for this comparison. Serum and/or plasma collected in serum separation tubes and/or EDTA tubes are stable up to 72 h at 2 °C-8 °C or up to 6 weeks at ≤−18 °C according to the manufacturer's package insert [12] . Viral nucleic acid was extracted in parallel using the cobas ×480 instrument and CAP and then was amplified and detected using cobas z480 analyzer and CTM.
Statistical analysis
Data were expressed as mean and standard deviation (SD). To determine precision, repeatability and total imprecision were calculated using one-way analysis of variance and expressed as coefficient of variation (%CV) after log transformation. Grubb's test was performed to detect outliers. Because manufacturer-claimed values for repeatability and total imprecision were not available [12] , we determined upper verification limit (UVL) according to the CLSI document EP 15-A3 [14] . UVL means the upper 95th percentile expected for imprecision estimates obtained in experiments similar in size and design to the user's precision verification study and can be calculated as F × %CV. The factor F is derived from the degree of freedom and the total number of test samples used in the entire precision verification study; in this study, each of the three samples was replicated 25 times, and F was set as 1.61 [14] . Linear regression was performed for linearity assessment and was expressed after log transformation. To assess linearity, the allowable random error across the measured concentration was defined based on the precision determined in this study. The total number of measurements was 24 for LOB, LOD and LOQ, respectively. The allowable error of LOQ was also defined based on the precision determined in this study. The proportion of measurement results that are consistent with the respective claim is calculated and compared with the appropriate boundary value with statistical power. The acceptance of observed proportion boundary is set at 85% for 20 measurements and at 87% for 30 measurements (H0: μ ≥ 95%, α = 0.05 or β = 0.05) [16] ; it was set approximately 85% in this study using 24 measurements. If the observed proportion is less than 85%, it is supposed to indicate that the observed results are not consistent with the claim. To compare the quantitative results of HBV detection between cobas HBV and CAP/CTM HBV, the PassingBablok regression and the mean differences for averaged logs by the Bland-Altman plot were analyzed on positive results by both systems. All the recorded data were demonstrated as a scatter plot for detecting outliers and identifying a systematic bias [19] . In the Passing-Bablok regression, the correlation coefficient (r) was accounted: ≤0.30 as negligible correlation; 0.30-0.50 as low correlation; 0.50-0.70 as moderate correlation; 0.70-0.90 as high correlation; and ≥ 0.90 as very high correlation [20] . In the BlandAltman plot, the results were interpreted informally to see how big the average discrepancy is and whether there is a trend of difference. If the differences or trends are not clinically important, the two methods were considered interchangeable [21] .
Statistical analysis was performed using Analyse-it Software (version 4.90.4 Analyse-it Software, Ltd., Leeds, UK) or MedCalc Software (version 17.9.7, MedCalc Software, Mariakerke, Belgium). p-Values less than 0.05 were considered statistically significant.
Results
Precision
Target values of control materials were 2.0, 4.0 and 6.0 log 10 IU/mL, and their mean ± SD values were 2.16 ± 0.08, 4.41 ± 0.05 and 6.02 ± 0.03 log 10 IU/mL. There was no outlier detected using Grubb's test. The precision ranged from 0.5% to 3.8%, and 3.8% was used to define allowable errors for the triplicates across the measured concentrations in linearity assessment and for the LOQ determination (Table 1) .
Linearity
HBV DNA quantitation by cobas HBV was linear for approximately seven orders of magnitude and showed first orders, ranging from 2.38 × 10 to 3.25 × 10 7 IU/mL ( Figure 1) . No outlier was found by visual examination of scatter plot. The observed data were within allowable error (<3.8%) among triplicates across the measured concentration.
Detection capability
All the 24 (100%) replicates showed the results of not detected for LOB verification. For LOD verification, 22 (91.7%) of 24 replicates showed the results of analyte detected, and the other two replicates were quantitative results (12.5 and 14.3 IU/mL). For LOQ verification, 9 (37.5%) of 24 replicates showed quantitative results. The remaining 15 replicates showed the results of analyte detected that were less than 10.0 IU/mL; therefore, the observed proportion boundary of LOQ could not be calculated (Table 2) .
Comparison
In 205 clinical samples (102 sera and 103 EDTA plasma), the viral load results were compared between cobas HBV and CAP/CTM HBV. Neither outlier nor systematic bias was detected on scatter plots. The Passing Bablok regression of correlation demonstrated very high correlations in total, sera and plasma samples (r = 0.995, all) (Figure 2A-C) . In the Bland-Altman plot, the mean differences in total, sera and plasma samples were 0.00, −0.07 and 0.06 log 10 IU/mL, respectively, without any trend of difference ( Figure 2D-F) . 
Discussion
This is the first study to verify the analytical performance of the HBV assay on cobas 4800 System. We evaluated its precision, linearity and detection capabilities, including LOB, LOD and LOQ, and compared the results of HBV DNA quantitation between cobas HBV on cobas 4800 System and CAP/CTM HBV on COBAS CAP/CTM system.
The manufacturer-claimed repeatability and the within-laboratory imprecision of cobas HBV are not available in the product insert [12] . We used two levels of cobas HBV/HCV/HIV-1 Control Kit (low and high) and one level of 1:1 mixture using low and high levels of cobas HBV/HCV/ HIV-1 Control Kit, and the target values of control materials were 2.0, 4.0 and 6.0 log 10 IU/mL. The precision of CAP/CTM HBV was reported to be less than 4.9% after log transformation [22] , and that of AdvanSure HBV real-time PCR system was reported to be less than 5.7% after log transformation [23] . In the present study, the precision of cobas HBV was less than or equal to 3.8% after log transformation, and the cobas HBV showed a good precision performance in comparison with existing assays (Table 1) .
The CLSI EP06-A suggests the hierarchy of accepted matrices: the ideal sample matrix is a patients' sample pool with an analyte concentration near the expected upper reportable limit that is diluted with another patients' sample pool having an analyte concentration at the expected lower limit [15] . The manufacturer's claimed measurable range of cobas HBV was from 10 to 1 × 10 9 IU/ mL. This study showed the linear range from 2.38 × 10 to 3.25 × 10 7 IU/mL for HBV detection, and the measurement error for every analyte was less than 2.84%. In the present study, we applied a strict limit of 3.8% for allowable error and the goal of linearity evaluation, and cobas HBV showed good linearity (Figure 1) . Consideration of random error is a crucial step for the linearity evaluation protocol [15] . There is a growing interest in biological variation and imprecision of biomarkers in clinical laboratories; however, no consensus or proposed guidelines on those concepts are available yet for viral NAAT, including HBV NAAT [24, 25] . Future studies will be necessary to address these issues.
We used the 4th WHO standard material to verify LOB, LOD and LOQ. The CLSI EP17-A2 requires a minimum of 20 total replicates across all samples and days [16] . We performed 24 measurements with four replicates per each two samples per each 3 days. The observed proportions of LOB and LOD were acceptable based on CLSI EP17-A2 [16] , and the verifications were deemed to be successful. However, the observed proportion of LOQ could not be calculated because, differently from the CTM, the cobas z480 analyzer does not provide relative quantitative results using threshold cycle and standard curve analysis when the analyte is detected less than LOQ (Table 2) .
According to the manufacturer's product insert, blood should be collected in serum separation, plasma preparation or EDTA tubes for the cobas HBV assay [12] . Although the manufacturer used 215 EDTA plasma and 170 serum samples, the correlation with the CAP/CTM HBV results is available only for the total samples without respect to the serum and plasma samples separately. We compared quantitative results by cobas HBV and CAP/CTM HBV using 102 sera and 103 EDTA plasma samples, and the cobas HBV and CAP/CTM HBV showed very high correlations in serum and plasma samples each as well as in total samples (Figure 2) .
Because manufacturer-claimed repeatability and within-laboratory imprecision were not available, we calculated the UVL to determine acceptance of precision evaluation. A limitation of this study is that the cobas z480 analyzer does not provide relative quantitative results using threshold cycle and standard curve analysis Total number of measurements is 24; therefore, the acceptable observed proportion boundary is set about 85% [16] . LOB, limit of blank; LOD, limit of detection; LOQ, limit of quantitation; B, blank; D, detection; Q, quantitation; ND, not detected; AD, analyte detected; NA, not available.
when the analyte detected is less than the LOQ. Accordingly, we could not complete LOQ verification according to the CLSI guideline. In comparison evaluation, we did not confirm HBV genotypes and could not demonstrate the possible analytical difference across HBV genotypes [12] .
HBV genotype varies across countries and ethnic backgrounds; in Korea, the prevalence of genotype C is nearly 100% [26, 27] . There are other limitations: a very good concordance on a broad concentration range is shown, but the number of samples assayed is quite limited; moreover, the quantitative assays for HBV DNA are mainly employed for monitoring, and having some data on patients monitoring during and/or after treatment would have added value to this study. The default sample processing volume for cobas HBV is 400 μL, and a sample processing volume of 200 μL could be chosen for low volume samples. For CAP/CTM HBV, however, the default sample processing volume is 500 μL. The cobas HBV on cobas 4800 System takes 3.5 h for 24 tests and 4.5 h for 96 tests, whereas the CAP/CTM HBV on CAP/CTM system takes 5.5 h for 24 tests and 8 h for 96 tests [12, 13] . Small processing volume and shorten turnaround time (TAT) might be helpful to optimize clinical laboratory workflow. Another limitation of this study is that these practical aspects of processing volume and TAT were not evaluated.
In conclusion, this is the first study to evaluate the analytical performance of the cobas HBV assay for the cobas 4800 System. It showed reliable analytical performance in terms of precision, linearity and detection capabilities, and its quantitative results were interchangeable with those of CAP/CTM HBV. The cobas HBV assay on cobas 4800 System could be a good laboratory option for HBV NAAT with reliable analytical performance and improved clinical laboratory workflow.
